Thiazolidinediones (also called glitazones) are a class of medicines that may be used for the treatment of type 2 diabetes. They are a type of oral hypoglycemic (a medicine that lowers blood glucose levels).

Thiazolidinediones or TZDs act by activating PPARs (peroxisome proliferator-activated receptors), a group of nuclear receptors, specific for PPARγ (PPAR-gamma, PPARG). They are thus the PPARG agonists subset of PPAR agonists. The endogenous ligands for these receptors are free fatty acids (FFAs) and eicosanoids.

2023年2月20日 · Thiazolidinediones are medications used to manage and treat type 2 diabetes mellitus. These medications may act as a nuclear transcription regulator and an insulin sensitizer. This activity illustrates the indications, mechanism of action, and contraindications for thiazolidinediones as valuable agents for managing type 2 diabetes. Objectives:

Thiazolidinediones are recommended for persons with type 2 diabetes who have poorly controlled blood glucose and high Hb A1c levels. What? Rosiglitazone (marketed as Avandia). Where? These pills work primarily by enhancing the body’s ability to respond to insulin. When? Why? These medications typically lower A1c levels by 1 – 1.5%.

Thiazolidinediones knew as “glitazones” are oral antidiabetic drugs used with a proper diet and exercise to control high blood sugar in people with type 2 diabetes mellitus (T2DM). Learn about uses, side effects, and drug names.

The thiazolidinediones increase insulin sensitivity by acting on adipose, muscle, and, to a lesser extent, liver to increase glucose utilization and decrease glucose production. One thiazolidinedione (pioglitazone) is currently available in the United States.

2019年1月15日 · Thiazolidinediones, also known as glitazones, are a group of oral anti-diabetic drugs designed to treat patients with type 2 diabetes. Classed as oral hypoglycemic drugs along with biguanides, they are taken once or twice daily with or without food and work by targeting insulin resistance – a core physiologic defect in those with type 2 diabetes.

Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular risk factors associated with insulin resistance have been well documented. TZD use has been limited because of concern about safety issues and side effects.

2024年6月13日 · Thiazolidinediones, or TZDs, help decrease blood glucose (sugar) levels by reducing insulin resistance and making the body respond to insulin. TZDs also reduce the amount of glucose produced by the liver.

A key scaffold: 2,4‐Thiazolidinedione is a widely recognised structural motif present in many therapeutic agents used for the treatment of diabetes mellitus. This review summarises some of the methods used to prepare biologically active members of this class and discusses the pharmacological potency of these compounds.